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Abstract
Background: Tuberculosis is one of the leading causes of death from infectious diseases worldwide, mainly after
the human immunodeficiency virus (HIV) epidemics. Patient with HIV-related illness are more likely to present with
severe TB due to immunosuppression. Very few studies have explored HIV/TB co-infection in critically ill patients.
The goal of this study was to analyze factors associated with long-term mortality in critically ill patient with
HIV-related disease coinfected with TB.
Methods: We conducted a retrospective study in an infectious disease reference center in Brazil that included all
patient with HIV-related illness admitted to the ICU with laboratory-confirmed tuberculosis from March 2007 until
June 2012. Clinical and laboratory variables were analyzed based on six-month survival.
Results: Forty-four patients with HIV-related illness with a confirmed diagnosis of tuberculosis were analyzed. The
six-month mortality was 52 % (23 patients). The main causes of admission were respiratory failure (41 %), severe
sepsis/septic shock (32 %) and coma/torpor (14 %). The median time between HIV diagnosis and ICU admission
was 5 (1–60) months, and 41 % of patients received their HIV infection diagnosis ≤ 30 days before admission. The
median CD4 count was 72 (IQR: 23–136) cells/mm3. The clinical presentation was pulmonary tuberculosis in 22
patients (50 %) and disseminated TB in 20 patients (45.5 %). No aspect of TB diagnosis or treatment was different
between survivors and nonsurvivors. Neurological dysfunction was more prevalent among nonsurvivors (43 % vs.
14 %, p = 0.04). The nadir CD4 cell count lower than 50 cells/mm3 was independently associated with Six-month
mortality (hazard ratio 4.58 [1.64–12.74], p < 0.01), while HIV diagnosis less than three months after positive serology
was protective (hazard ratio 0.27, CI 95 % [0.10–0.72], p = 0.01).
Conclusion: The Six-month mortality of HIV critically ill patients with TB coinfection is high and strongly associated
with the nadir CD4 cell count less than 50 cels/mm3.
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Background
Tuberculosis remains a global health issue and the lead-
ing causes of death from infectious diseases worldwide,
mainly after the human immunodeficiency virus (HIV)
epidemics. The main population affected by TB
mortality is HIV-positive individuals. Throughout 2014,
1.5 million deaths occurred, of which 0.4 million were
among seropositive patients [1]. Tuberculosis prophy-
laxis and treatment is still suboptimal in patients with
HIV coinfection in developing countries, even with novel
diagnostic tests and antimicrobial agents [1].
Fifteen percent of new TB cases in Brazil are among
HIV-infected individuals, which reinforces the recom-
mendation for systematic TB screening for hospitalized
patients with HIV-related disease [2–4]. HIV-positive
persons that present with advanced immunosuppression
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more frequently present with hematogenous dissemin-
ation of the bacillus and multiorgan involvement, and
are frequently smear-negative, requiring blood cultures
and invasive procedures for diagnosis [5–8].
HIV-TB coinfection accounts for 26.6 % of TB mortal-
ity rate [1], and the subgroup of patients that require
ICU has an even worse prognosis [4]. Respiratory failure
is the most frequent cause of ICU admission of patients
with HIV-related illness, and TB is associated with dis-
tinct prevalence according to the geographic location
where the studies are performed [9–11].
Very few studies have explored HIV/TB coinfection in
critically ill patients [9, 12]. Disseminated presentation
of TB, low serum albumin levels, delayed diagnosis and
multilobar lung involvement have been identified as
markers of poor prognosis [8, 9, 13, 14]. Additionally,
there is uncertainty about absorption of anti-
tuberculosis medications, and drug interactions with
antiretroviral therapy are still of concern, mainly when
rifampicin and protease inhibitors are prescribed simul-
taneously [8, 10].
The purpose of this study was to identify factors asso-
ciated with six-month mortality of critically ill patients
with HIV-related disease, with confirmed diagnosis of




This is a retrospective study conducted at the ICU of
the National Institute of Infectious Disease at Oswaldo
Cruz Foundation (FIOCRUZ) in Rio de Janeiro, Brazil.
Our institution has provided care to HIV-positive pa-
tients since 1986. There are currently over 3.300 HIV-
positive adult under active follow-up at Outpatient
Clinic. Cohort characteristics have been published else-
where [15, 16]. We admit approximately 60–70 patients
with HIV-related disease per year in the ICU.
Definitions, selection of participants and data collection
Study procedures
All files of patients with HIV-related disease admitted to
the ICU who received TB treatment from March 2007
to June 2012 were retrospectively reviewed. Only pa-
tients with laboratory confirmed tuberculosis were in-
cluded in this report. The follow-up for six-month
survival was checked through consulting electronic data
chart of ambulatory and hospital assistance.
Clinical variables related to HIV infection were: cART
exposure, time from HIV diagnosis until ICU admission,
nadir CD4 cell count, CD4 cell count and HIV viral load
recorded at ICU admission or collected in the previous
three months prior to hospital admission. Variables for
tuberculosis infection were: clinical presentation of
tuberculosis (pulmonary or disseminated), clinical speci-
mens that allowed microbiological TB confirmation,
anti-tuberculosis drugs prescribed while staying in the
ICU, and Mycobacterium tuberculosis resistance diag-
nosed by culture.
The severity of illness was evaluated using the Simpli-
fied Acute Physiological Score (SAPS) II and Sequential
Organ Failure Assessment score (SOFA). The SAPS II
score assigns points based on age, type of admission
(scheduled surgical, unscheduled surgical, or medical),
12 physiological variables, and three underlying disease
variable (AIDS, metastatic cancer, and hematologic ma-
lignancy); this score expresses the level of acute severity
along with age and the presence of these severe comor-
bidities in the first 24 h after ICU admission [18]. The
score varies from 0 to 163 points, and the higher the
SAPS II value, the less is the probability of survival.
SOFA score is a semi-quantitative score of six organ
dysfunctions, named cardiovascular, respiratory, neuro-
logical, hematological, hepatic and renal dysfunctions
[19]. It classifies a range of six organ dysfunctions: car-
diovascular (hypotension or use of vasopressors); re-
spiratory (PaO2/FiO2 rate); neurological (Glasgow Coma
Scale); renal (serum creatinine level and/or daily diur-
esis); hepatic (serum bilirubin level); and hematological
(platelets level). The score goes from 0 to 24 points, and
it can be calculated on a daily basis, in order to evaluate
the patient’s improvement or worsening. SOFA also
gives qualitative information about the Multiple Organ
Dysfunction Syndrome (MODS). For ease of interpret-
ation, we also evaluated the initial SOFA score (day 1),
since one score higher than 11 points is associated with
less than 20 % chance of survival [20]. We also evaluated
the use of vasoactive drugs, non-invasive and invasive
ventilation support, and hemodialysis. We classified all
ICU admission diagnoses as: respiratory insufficiency,
severe sepsis or septic shock, coma/torpor and miscel-
laneous [21].
Demographic and clinical data were categorized ac-
cording to the survival after six months. The results
were displayed as frequency (percentage), median values
and interquartile range. If a patient had multiple ICU
admissions, only the first was included in this analysis.
The ICU team, infectious disease specialist and family
members in accordance with local practices shared deci-
sions regarding withholding or withdrawal of treatment.
Case definition
Tuberculosis was considered confirmed if the bacterio-
logic case definition was met: direct visualization of
acid-fast bacilli (Ziehl-Neelsen stain), (“smear positive”),
or a positive culture for Mycobacterium tuberculosis in
Lowenstein-Jensen or liquid medium (MIGT). A histo-
pathological result consistent with Tuberculosis in a
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patient with high clinical suspicion was also considered
a confirmed case. Patients were excluded if central ner-
vous system (CNS) involvement was highly suggested by
CT scan and/or CNS fluid exams, since CNS tubercu-
losis infection carries a much higher mortality per se
and could overscore on CGS [22]. Besides the high mor-
tality rate it could distort the analysis of the group, and
therefore it should be analyzed separately.
Combined antiretroviral treatment (cART) exposure
before ICU entry meant any cART use regardless of ad-
herence to the treatment. We defined cART as adminis-
tration of three antiretroviral drugs belonging to at least
two classes (i.e., nucleoside reverse-transcriptase inhibi-
tor, non-nucleoside reverse-transcriptase inhibitor, pro-
tease inhibitor, integrase inhibitor).
In our population, we had two scenarios of the admin-
istration of TB drugs while in the ICU, according to the
hemodynamic status. In the case of hemodynamic un-
stable patients, TB drugs were delivered intravenously;
fluoroquinolones and aminoglycosides were the drugs of
choice. When the patient was hemodynamically stable,
TB drugs could be delivered per enteral or oral route;
the combination of Rifampicin (R), Isoniazid (H), Pyrazi-
namide (P), Ethambutol (E) were the preferred drugs
given by oral/enteral route.
Disseminated TB was defined when: thoracic X-ray or
CT scan showed a pattern that indicated dissemination;
two non-contiguous sites were involved in accordance
with WHO 2013; or Mycobacterium tuberculosis was re-
covered from the bloodstream [1].
Drug resistance was defined as resistant to ≥ 1 drug
[17], and Multidrug-resistant tuberculosis (MDR) de-
fined as TB caused by strains of Mycobacterium tuber-
culosis that are resistant to at least isoniazid and
rifampicin [23].
Laboratory procedures
Resistance towards anti-TB drugs was determined by
culture methods using liquid media or Lowenstein-
Jensen slants.
Statistical analysis
We analyzed the clinical and laboratory variables ac-
cording to six-month survival after ICU admission using
GraphPad Prism version 6.0 for MAC OS X (GraphPad
Software, San Diego, CA, USA) and Epi Info™ version
7.1 (Centers for Disease Control, Atlanta, GA, USA).
The numerical demographic variables were expressed as
the median and the interquartile range (IQ 25 –75 %).
All of the numerical variables were tested for normality
using the Kolmogorov-Smirnov test. We compared con-
tinuous variables using a t-test (parametric distribution)
and the Mann–Whitney U test (nonparametric distribu-
tion). The categorical variables were compared using the
chi-squared test and Fisher’s exact test. We categorized
two numerical variables, since the dispersion was wide:
CD4 cell count (below 50 cells/mm3) and time since
HIV diagnosis (recent HIV means less than three
months after positive HIV serology). We performed the
survival analysis with Cox proportional hazards to
analyze factors associated with six-month survival,
selecting variables with p values lower than 0.2 in the
univariate comparison. A Kaplan-Meier curve was con-
structed based on independent factors associated with
six-month survival.
Results
Clinical characteristics of patient with HIV-related illness
with tuberculosis in the ICU
During the five years study period, 267 HIV/AIDS patients
were admitted to the ICU and 63 received tuberculostatic
treatment. Among these, 49 had laboratory-confirmed tu-
berculosis; four patients were excluded because of con-
firmed TB CNS involvement and one patient was
transferred to another hospital. A total of 44 patients
with HIV-related disease with confirmed TB were in-
cluded in the study. All patients were followed up to
six months after ICU discharge. The ICU mortality
was 48 % (21 patients), one patient died after being
transferred to the hospital ward and one patient died
within the following six months after ICU discharge
(Fig. 1).
The median age was 34 (IQR: 19–44.5) years, with a
predominance of males (70 %) (Table 1). The main rea-
sons for ICU admission were respiratory failure (41 %),
severe sepsis/septic shock (32 %), coma/torpor (14 %),
and miscellaneous (13 %). The SAPS II score was 47
(IQR: 37–55) points, and the SOFA score on day 1 of
the ICU stay was 4 (IQR: 1–8) points. Mechanical venti-
lation was needed in 63 % of patients.
The main differences between survivors and nonsurvi-
vors for six-month mortality were: nadir CD4 cell count,
median time length between HIV-infection diagnoses
and ICU admission, SOFA score, and neurological dys-
function. Twenty-one (45 %) patients had a recent HIV
diagnosis (within three months before hospital admis-
sion). The most recent median CD4 cell count was 36
[IQR: 15–80] in nonsurvivors vs. 100 [IQR: 58–243]
cells/mm3 in survivors (p = 0.01); with a median time be-
tween CD4 cell count and ICU admission – 0.5 months
(IQR: -2.25–0).
Twenty-five (57 %) patients were previously exposed
to cART, and only 4 (9 %) presented with undetectable
viral load (less than 50 copies/ml). Combined ART was
used in 17 (39 %) patients while in the ICU, with no stat-
istical difference in both, hospital mortality (52 % vs
29 %, p = 0.23) and in six months survival (48 % vs 30 %
p = 0.35). There was no statiscally difference in six-
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month mortality between survivors and nonsurvivors
using cART while in the ICU (48 % vs 30 %, p = 0.35).
There was no difference in six-month mortality between
survivors and nonsurvivors using cART during the first
week of ICU stay (38 % vs 17 %, p = 0.09), or during the
2nd week (33 % vs 35 %, p = 0.78). None of the patients
presented IRIS nor revealed an unmasked infection
while taking cART in the ICU.
Tuberculosis diagnosis and treatment
No aspect of TB diagnosis or treatment was different in
survivors or nonsurvivors. Twenty-two pulmonary TB
cases (50 %) and 22 disseminated (50 %) TB cases were
equally distributed between the 2 groups (Table 1). Tu-
berculosis was diagnosed from respiratory samples in
the majority of cases. Thirty-two (73 %) patients were di-
agnosed through direct visualization of the bacillus using
the Ziehl-Neelsen technique (27 in the sputum and 5 in
the bronchoalveolar lavage); the diagnosis was only
made through culture of respiratory specimens in 5
(11 %) patients. Bacteremia due to Mycobacterium tuber-
culosis was found in 6 (14 %) patients. Eleven (25 %) pa-
tients required invasive procedures for TB diagnosis,
such as organ biopsy. The main TB regimens prescribed
were per oral or enteral routes in 16 patients, while the
addition of intravenous drugs (mostly aminoglycosides
and quinolones) was chosen in 28 patients. The combin-
ation of oral/enteral drugs was composed by HRZ (n =
8) or HRZE (n = 8) schemes. Intravenous fluoroquino-
lones and aminoglycosides were prescribed in 27 (61 %)
and 22 (50 %) patients, respectively.
We identified resistance to M. tuberculosis in specimen
cultures from 5 (11 %) patients: resistance to streptomycin
(n = 4), isoniazid (n = 2), and rifampin (n = 1). From these
five patients, only one patient with isolated resistance
to streptomycin survived; the other four patients with
a pattern of resistance died. None of 44 patients in-
cluded had multidrug resistant Mycobacterium tuber-
culosis strains.
Organ dysfunctions
Although not statistically significant on day 1 of ICU ad-
mission, the SOFA score was higher among non-survivors
(p = 0.08) (Table 1). For this reason, we decided to deter-
mine if any of the six organ dysfunctions could be as-
sociated with six-month survival. Only neurological
dysfunction was statistically different: 10 (43 %) non-
survivors vs. 3 (14 %) survivors presented with neuro-
logical dysfunction, p = 0.04. Neurological dysfunction
was described as GCS of 13–14 points (somnolence) in 9
patients, and GCS of 8–10 points (torpor) in four pa-
tients. One patient had seizures, two patients had gait
disturbances and one patient had paresthesia. None
had neck stiffness, delirium [24] or intracranial hyper-
tension. Of the four patients with a GCS of less than
12 points, all had head CT scans and three had liquor
studies: three patients were diagnosed with neurotox-
oplasmosis and one patient had normal head CT
scan.
Six-month outcome
The nadir CD4 cell counts lower than 50 cells/mm3 was
independently associated with six-month mortality (haz-
ard ratio 4.58 [1.64–12.74], p = 0.004), while recent HIV
diagnosis (less than three months after positive serology)
was protective (hazard ratio 0.27, CI 95 % [0.10–0.72],
p = 0.01) (Table 2). We observed a lower six-month
Fig. 1 Flow diagram for study inclusion
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survival in patients with nadir CD4 cell counts lower
than 50 cells/mm3 (log rank test p = 0.006) (Fig. 2).
Discussion
The coinfection HIV-TB presented a high long-term
mortality in our cohort. The nadir CD4 cell count was
the independent marker for six-month mortality, while a
HIV diagnosis up to three months before hospital ad-
mission was protective among these severely ill HIV-TB
patients. No aspect of tuberculosis presentation or treat-
ment influenced the outcome. Among the organ dys-
functions, neurological dysfunction was more frequent
in nonsurvivors, even after the exclusion of those pa-
tients with primary TB CNS involvement.
HIV infection and critical illness
Since the beginning of the HIV epidemic, respiratory
failure has been the main reason for ICU admission with
the spectrum of etiological agents changing according to
the geographic region and cART access [25–28]. Influ-
enza, pneumococcal vaccination and TB background
prevalence also influence the main causes of respiratory
disease in this population [29–32]. Tuberculosis is highly
prevalent in Brazil, mainly in Rio de Janeiro, and the
Table 1 Characteristics critically ill HIV patients coinfected with TB (laboratory-confirmed) diagnosis, including the characteristics of
Tuberculosis (TB) presentation and treatment and the prevalence of organ dysfunctions at ICU admission (N = 44)
HIV/AIDS and Tuberculosis (N = 44) Survivors (N = 21) Non-survivors (N = 23) p value
Age (years) 34 (19.25–44.5) 32 (27–42.5) 36 (30–46) 0.15
Gender (male) 31 (70 %) 14 (67 %) 17 (74 %) 0.74
Nadir CD4a 54 (17–96) 73 (30–177) 23 (14–84) 0.04
Viral load (×103 copies/mm3)b 113,637 (2,995–365,663) 35,149 (212.3–300,184) 169,133 (35,405–419,382) 0.13
Length of time since HIV diagnosis (months) 5 (1–60) 1 (1–16) 28 (1–72) 0.03
cART use while in the ICU 17 (38.6 %) 10 (48 %) 7 (30 %) 0.35
Mechanical ventilation use on ICU day 1 21 (48 %) 8 (42 %) 13 (52 %) 0.56
Vasoactive drug use on ICU day 1 12 (26 %) 5 (24 %) 7 (27 %) 0.99
SAPS II score (points) 47 (37–55) 48 (37–57) 46 (38–54) 0.27
SOFA score on day 1 (points) 4 (1–8) 1 (0–7) 5 (2–8) 0.08
Isolated TB pulmonary presentation 22 (50 %) 10 (48 %) 12 (52 %) 1.00
Disseminated TB presentation 22 (50 %) 11 (52 %) 11 (48 %) 1.00
TB treatment before ICU admission 25 (57 %) 11 (52 %) 14 (61 %) 0.76
TB treatment
- only by enteral drugs 16 (36 %) 10 (48 %) 6 (26 %) 0.21
- adding intravenous drugs 28 (64 %) 11 (52 %) 17 (74 %)
TB treatment: Δ ICU admission 0 (-5–+21) -5 (-23–+2) -5 (-21–0) 0.09
TB treatment before ICU 25 (57 %) 11 (52.4 %) 14 (61 %) 0.76
Organ Dysfunctions
Cardiovascular 18 (41 %) 7 (33.3 %) 11 (48 %) 0.37
Respiratory 15 (34 %) 5 (24 %) 10 (43 %) 0.21
Renal 14 (32 %) 5 (24 %) 9 (39 %) 0.34
Neurological 13 (29 %) 3 (14 %) 10 (43 %) 0.04
Hepatic 9 (20 %) 5 (24 %) 4 (17 %) 0.71
Hematological 9 (20 %) 3 (14 %) 6 (26 %) 0.46
Comparison between survivors and nonsurvivors for six-month survival. Results were expressed as the median and the interquartile interval
adata available for 39 patients
bdata available for 35 patients
Δ:time from starting TB treatment and beeing admitted to ICU. Negative (-) mean prior to ICU admission and positive (+) means after ICU admission
Table 2 Cox proportional analysis and adjusted hazard ratio for
six-month mortality (95 % CI) of critically ill patients with HIV-
related disease with tuberculosis (N = 44)
Variable Adjusted Hazard ratio
for six-month mortality
p value
Nadir CD4 cell count less
than 50 cells/mm3
4.58 [1.64–12.74] 0.004
Age at inclusion 1.03 [0.99–1.08] 0.07
SOFA score at ICU admisson 1.09 [0.97–1.22] 0.13
Recent HIV diagnosis at admissiona 0.27 [0.10–0.72] 0.009
arecent HIV diagnosis: less than three months of HIV positive serology
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HIV infection epidemic has made TB a common cause
of opportunistic infections responsible for AIDS diagno-
sis in our population [2, 33]. Rio de Janeiro has one of
the worst scenarios in regards to the Tuberculosis epi-
demic in Brazil. In 2012, 10,649 new tuberculosis cases
were diagnosed in Rio de Janeiro State, with an inci-
dence rate of 65.6/100.000 person-years, a rate much
higher than the overall country incidence rate of 35.8/
100.000 person-years. The mortality rate among TB pa-
tients from Rio de Janeiro is the second highest in the
entire country, reaching 5.1/100.000 person-years.
Respiratory failure is the main reason for ICU admis-
sion among pulmonary HIV-TB patients [8–10], as we
described in our population, even though 45 % of pa-
tients present with disseminated tuberculosis. Isolated
extrapulmonary disease was uncommon (5 %).
Severe immunosuppression caused by HIV infection is
a known risk factor for tuberculosis [7]. As immunosup-
pression evolves, the TB disease spectrum changes from
its classic pulmonary presentation of unilateral upper
lobe infiltrate to a broad range of nonspecific signs and
symptoms related to hematogenic spread of the bacillus.
The myriad of presentations of TB in the population
with HIV-related disease is associated with challenges in
establishing the diagnosis and higher mortality [33]. Our
high proportion of disseminated TB (45 %) is due to the
advanced immunodeficiency status of our population,
with median CD4 cell counts of 72 cells/mm3, which
were lower than previously reported (109 and 112 CD4
cells/mm3) [28,29]. CD4 cell count is thought to be an
unreliable predictor of ICU mortality, according to Mor-
ris and colleagues, when compared to other known risk
factors, such as mechanical ventilation, low serum albu-
min and APACHE II score [11, 34–37]. However, others
authors believe that CD4 cell count does have a correl-
ation with a poorer prognosis [25, 38–40]. Low CD4
counts (<200 cells/mm3) have been associated with ICU
mortality in HIV patients with TB [41]. In the present
study, we found that patients with higher nadir CD4 cell
counts were more likely to be alive six months after hos-
pital discharge. These data are supported by the idea
that CD4 cell counts at ICU admission are a better
marker of long-term prognosis [42]. We preferred nadir
than recent CD4 cell count because opportunistic infec-
tions and concomitant acute infections can lower the
CD4 cell count [45]. Alongside with the low nadir CD4
cell count, we wanted to emphasize that we also ob-
served a low median CD4 count close to ICU admission
meaning that our population represents a profoundly
immunocompromised population. Also, nadir CD4 cell
count it is better marker of prognosis and disease evolu-
tion in HIV infected population [43, 44]. We also found
Fig. 2 Kaplan-Meier plot of six-month survival in critically ill patients with HIV-related disease and tuberculosis, based on nadir CD4 cell count less
than 50 cells/mm3. Log-rank test p = 0.006
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that recent HIV diagnosis was associated with protective
effect for long term survival. This variable should be
evaluated with caution: there is not an accurate correl-
ation of the moment of first HIV positive serology and
the time since HIV infection began. Some patients are
admitted with recent HIV diagnosis and very low nadir
CD4 count, although they were previously less exposed
to bacterial and multilple oportunistic infections and to
the HIV infection per se, than their peers with long
known HIV diagnosis and non-adherence to cART. This
state of chronic immunosuppression by HIV and oppor-
tunistic infections may have contributed to a lower sur-
vival rate in this population, as shown previously in a
heterogeneous group of studies with and without cART
influence [11, 30, 58].
As show earlier from our institution’s cohort, the HIV
diagnosis frequently occurs during an advanced im-
munodeficiency state, which can be associated with a
high prevalence of tuberculosis [46]. Earlier diagnosis is
fundamental to diminish the complications of the ad-
vanced immunodeficiency.
Delivering cART in critically ill patients is still contro-
versial. The limited availability of intravenous medica-
tions, potential drug-to-drug interactions, erratic
gastrointestinal absorption and the risk of unmasking in-
fections and IRIS are considerations in the setting of
critically ill patient with HIV-related disease [37, 38, 53].
The administration of cART did not influence short- or
long-term survival in our study, but we cannot conclude
that cART administration in the ICU is not beneficial
since it was not possible to assure adherence of all pa-
tients taking cART after hospital discharge, which is fun-
damental to the success of the treatment. In the present
study, we did not find Immune Reconstitution Inflam-
matory Syndrome (IRIS) criteria in any case, nor did we
find any severe adverse reactions attributed to cART.
Characteristics of tuberculosis infection
The recovery of M. tuberculosis from blood cultures is
suggestive of disseminated TB, and we found bacteremia
in 14 % of patients. This is a common etiologic agent of
sepsis in population with HIV-related disease, as ob-
served in two published works by our group and other
groups [11, 29, 43–49]. Research suggests that patients
with disseminated and extra-pulmonary forms of tuber-
culosis may represent a special group that may be asso-
ciated with worse outcomes, including greater risk for
the tuberculosis immune reconstitution inflammatory
syndrome [50]. TB treatment in the acute phase of crit-
ically ill patients can often be suboptimal [51, 52] be-
cause first line drugs are only available in oral
formulations. One could suppose that intravenous treat-
ment could improve outcomes (fluoroquinolones and
aminoglycosides). However, in this case series, we found
a high proportion of critically ill patients using rifampin,
isoniazid and pyrazinamide, and half of our patients re-
ceived intravenous quinolones and/or aminoglycosides
as the first treatment for TB with no difference in six-
month survival.
Risk factors for long-term mortality
The six-month mortality observed in our study was high
(52 %), but lower than reported from other retrospective
studies involving patients with TB admitted to the ICU
(hospital mortality 22–67 %) [10, 41, 54]. Another inter-
esting point was that the disseminated form of TB had a
similar mortality to pulmonary presentation (45 % and
50 %, respectively). This may be different from another
study, which enrolled 46 HIV-TB patients, including sus-
pected cases of TB, although we included only confirmed
cases [10]. Finally, improvements in the care of critically
ill patients, such as implementation of protective ventila-
tor strategies with low tidal volume, conservative fluid
strategy for Acute Respiratory Distress Syndrome (ARDS),
and early sepsis goals, have added benefits and have re-
cently had an impact on lower mortality rates [28, 34, 55].
This study highlights neurological dysfunction as being
an important marker for mortality among critically ill HIV-
TB patients. These findings cannot be attributed to enceph-
alitis or meningitis that is primarily caused by TB. We ex-
cluded CNS involvement (encephalitis or meningitis),
which carries a poorer prognosis [56, 57]. All patients with
GCS ≤ 11 had a lumbar puncture performed. The majority
of our neurological findings were mild; most of them were
classified as torpor. As shown previously, low GCS at
admission can be a reliable predictor of ICU mortality
[35, 58]. In our analysis, neither SOFA nor SAPS II was
able to predict survival. Another two studies have found
correlation between higher SAPS II and ICU mortality
[35, 51]. Zahar et al. investigated laboratory-confirmed tu-
berculosis cases, 38 % were patients with HIV-related, all
with respiratory failure, and the majority with a pulmon-
ary presentation; higher SAPS II (approximately 45 points)
and the presence of more than one organ failure were sig-
nificantly associated with mortality [51]. Meybeck et al.
showed that SAPS II was significantly higher in nonsurvi-
vors (approximately 55 points) with an odds ratio of 1.05
per point [35]. The SAPS II score was similar between six-
month survivors and nonsurvivors in our study, while
SOFA scores on the day of ICU admission trended to-
wards being higher in nonsurvivors (p = 0.08).
Limitations of the study
We realize that our study has several limitations. First, it
is a retrospective single-center study conducted in a spe-
cialized infectious disease hospital, and these findings
cannot be extrapolated to other centers. The fact that
we did not find IRIS in our population may due to the
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retrospective nature of the study since we did not have
clear definitions since the beginning of our cohort. The lim-
ited number of patients (44 patients) is another limitation
of our study since we are exploring a very specific popula-
tion. However, the results here presented should increase
awareness to important factors that may contribute to a
better management of HIV-TB patients in the ICU, and for
pointing to future researches. Regarding the neurological
findings, due to its retrospective nature, we were not able
to detect broader neurological involvement, such as delir-
ium and intracranial hypertension [58]. Delirium screening
using the Confusion Assessment Method (CAM-ICU) as-
sessment is not a routine practice at our institution [24].
Conclusions
The six-month mortality of HIV critically ill patients
with TB coinfection is high and strongly associated with
the nadir CD4 cell count less than 50 cels/mm3. Neuro-
logical dysfunction may be associated with poor survival,
even without primary CNS involvement.
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